• Xencor (XNCR) Phase 2 Results of XmAb5871 for IgG4-RD

       (0 reviews)

    Clinical and Regulatory
    Event Type: Phase 2 Results
    Timing: H1 2017
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Other
    Indication: IgG4-RD
    Lead Indication?: No
    Treatment Name: XmAb5871

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Xencor
    Stock Symbol: XNCR
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://investors.xencor.com/releasedetail.cfm?ReleaseID=977312
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement



    XmAb5871 is a first-in-class monoclonal antibody that targets CD19 with its variable domain and that uses Xencor's XmAb immune inhibitor Fc domain to target FcγRIIb, a receptor that inhibits B-cell function. In March 2016, Xencor initiated a Phase 2 clinical study for the treatment of IgG4-RD and a Phase 2 clinical study for the treatment of SLE.

    Today, Xencor will discuss the trial design of its ongoing Phase 2 studies in IgG4-RD and SLE. Initial data from the IgG4-RD trial is expected in the first half of 2017 and initial data from the SLE trial is expected in 2018. A Phase 1 study with a subcutaneous formulation of XmAb5871 is expected to begin this year with initial data expected in 2017.



      Report Event

    User Feedback

    There are no reviews to display.